Vertex Pharmaceuticals has raised the upper end of its annual revenue forecast, driven by robust demand for its cystic fibrosis treatments. The company now expects its annual revenue to be between $13.1 billion and $13.2 billion, compared to its previous forecast of $12.95 billion to $13.1 billion.

Cystic Fibrosis Treatments

Vertex’s new cystic fibrosis drug, once-daily triple combination therapy Alyftrek, brought in sales of $573.6 million during the second quarter, compared to $156.8 million a year ago. The company’s older cystic fibrosis drug, combination therapy Trikafta, posted quarterly sales of $2.50 billion, missing estimates of $2.65 billion.

Cystic fibrosis is a rare and progressive genetic disorder caused by the absence of a protein regulating salt and water transport in and out of cells, leading to severe respiratory and digestive problems. Vertex’s treatments have been instrumental in improving the lives of those affected by this condition.

Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.